Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
adolescents
adults |
| gptkbp:alternativeName |
ritlecitinib
|
| gptkbp:approvalYear |
2023
|
| gptkbp:approvedBy |
gptkb:United_States
|
| gptkbp:ATCCode |
D11AX30
|
| gptkbp:brand |
Litfulo
|
| gptkbp:CASNumber |
1623593-24-6
|
| gptkbp:clinicalTrialPhase |
Phase 3
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:hasMolecularFormula |
C22H21N7O2S
|
| https://www.w3.org/2000/01/rdf-schema#label |
PF-06651600
|
| gptkbp:indication |
alopecia areata
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
JAK3 inhibitor
TEC family kinase inhibitor |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea headache acne increased creatine phosphokinase |
| gptkbp:target |
gptkb:JAK3
TEC family kinases |
| gptkbp:bfsParent |
gptkb:JAK3
|
| gptkbp:bfsLayer |
7
|